Vtv Theraptcs Cl A (VTVT)

$41.50 +3.19 (8.33%)
Market Cap 139.46M
Revenue (ttm) 1.02M
Net Income (ttm) -18.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,809.80%
Debt to Equity Ratio 0.00
Volume 39,255
Avg Vol 16,666
Day's Range N/A - N/A
Shares Out 3.94M
Stochastic %K 90%
Beta 0.48
Analysts Strong Sell
Price Target $51.20

Company Profile

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a lic...

Industry: Biotechnology
Sector: Healthcare
Phone: 336 841 0300
Fax: 336 841 0310
Address:
3980 Premier Drive, Suite 310, High Point, United States
dcajic2
dcajic2 Feb. 3 at 5:20 PM
$VTVT it does seem interesting. Volume decent. Just adding a few more shorts. Just don’t see why bullish yet. Could be super bullish but without any news and no way of making any money soon to me good opportunity to short.
0 · Reply
km1663
km1663 Feb. 3 at 5:08 PM
$VTVT Nice continuation in SP and volume which is already 218% higher than the normal 65 daily average!
0 · Reply
jarich7
jarich7 Feb. 3 at 4:36 PM
$VTVT
0 · Reply
GDS_investing
GDS_investing Feb. 3 at 4:23 PM
$VTVT very nice volume is running up LONG
0 · Reply
GDS_investing
GDS_investing Feb. 3 at 3:37 PM
$VTVT looking great and strong high volume so far we low float volume is the key we need to cross 44$ for next fast targets 56 and 86$ area (* 120 240 480*) end of the year imo LONG and STRONG $VTVT watch $FATN $GXAI $SNDK $SOXL
0 · Reply
LongBallBarn
LongBallBarn Feb. 3 at 3:09 PM
$VTVT happening
0 · Reply
Bullfinch
Bullfinch Feb. 2 at 9:29 PM
$VTVT https://ir.vtvtherapeutics.com/sec-filings/sec-filing/8-k/0001641489-26-000002
0 · Reply
FBTS_KD
FBTS_KD Feb. 2 at 8:45 PM
$VTVT first time we’ve heard about HPP737 in a while. Interesting.
0 · Reply
hollypine4comcast
hollypine4comcast Feb. 2 at 8:32 PM
$VTVT We need a strong encouraging news release before we will see any sustained price movement. This management team does not communicate with retail. I will just hold on but I am
0 · Reply
LongBallBarn
LongBallBarn Feb. 2 at 7:43 PM
$VTVT
0 · Reply
Latest News on VTVT
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

Feb 2, 2026, 8:00 AM EST - 1 day ago

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

Dec 18, 2025, 4:05 PM EST - 6 weeks ago

vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 4:15 PM EST - 3 months ago

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

Oct 9, 2025, 8:00 AM EDT - 4 months ago

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

Sep 15, 2025, 8:00 AM EDT - 5 months ago

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 4:57 PM EDT - 5 months ago

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 5 months ago

vTv Therapeutics to Participate in Upcoming September Investor Conferences

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Sep 2, 2025, 8:00 AM EDT - 5 months ago

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:15 PM EDT - 6 months ago

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Aug 11, 2025, 8:00 AM EDT - 6 months ago

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

Aug 7, 2025, 8:00 AM EDT - 6 months ago

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

Jun 11, 2025, 8:00 AM EDT - 8 months ago

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025, 9:00 AM EDT - 9 months ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025, 4:01 PM EDT - 9 months ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025, 12:00 PM EDT - 9 months ago

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 20, 2025, 5:35 PM EDT - 11 months ago

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges

Mar 17, 2025, 1:59 PM EDT - 11 months ago

FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Mar 17, 2025, 8:30 AM EDT - 11 months ago

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Dec 9, 2024, 7:33 AM EST - 1 year ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

Dec 2, 2024, 4:05 PM EST - 1 year ago

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Aug 8, 2024, 4:15 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Jul 26, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

Jun 24, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 28, 2024, 8:00 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

May 9, 2024, 4:51 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Mar 19, 2024, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 13, 2024, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Mar 4, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

Mar 1, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Feb 28, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Feb 22, 2024, 4:00 PM EST - 2 years ago

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Nov 9, 2023, 4:30 PM EST - 2 years ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Nov 2, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Nov 1, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

Sep 27, 2023, 8:30 AM EDT - 2 years ago

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Sep 18, 2023, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Aug 11, 2023, 4:30 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Aug 10, 2023, 8:33 AM EDT - 2 years ago

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Jun 16, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

Jun 15, 2023, 7:33 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 24, 2023, 9:00 AM EDT - 2 years ago

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

May 11, 2023, 4:15 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

Apr 20, 2023, 8:00 AM EDT - 3 years ago

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 6, 2023, 5:56 PM EST - 3 years ago

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Mar 6, 2023, 8:02 AM EST - 3 years ago

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

Feb 27, 2023, 8:02 AM EST - 3 years ago

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

Feb 1, 2023, 5:00 PM EST - 3 years ago

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

Jan 9, 2023, 8:00 AM EST - 3 years ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

dcajic2
dcajic2 Feb. 3 at 5:20 PM
$VTVT it does seem interesting. Volume decent. Just adding a few more shorts. Just don’t see why bullish yet. Could be super bullish but without any news and no way of making any money soon to me good opportunity to short.
0 · Reply
km1663
km1663 Feb. 3 at 5:08 PM
$VTVT Nice continuation in SP and volume which is already 218% higher than the normal 65 daily average!
0 · Reply
jarich7
jarich7 Feb. 3 at 4:36 PM
$VTVT
0 · Reply
GDS_investing
GDS_investing Feb. 3 at 4:23 PM
$VTVT very nice volume is running up LONG
0 · Reply
GDS_investing
GDS_investing Feb. 3 at 3:37 PM
$VTVT looking great and strong high volume so far we low float volume is the key we need to cross 44$ for next fast targets 56 and 86$ area (* 120 240 480*) end of the year imo LONG and STRONG $VTVT watch $FATN $GXAI $SNDK $SOXL
0 · Reply
LongBallBarn
LongBallBarn Feb. 3 at 3:09 PM
$VTVT happening
0 · Reply
Bullfinch
Bullfinch Feb. 2 at 9:29 PM
$VTVT https://ir.vtvtherapeutics.com/sec-filings/sec-filing/8-k/0001641489-26-000002
0 · Reply
FBTS_KD
FBTS_KD Feb. 2 at 8:45 PM
$VTVT first time we’ve heard about HPP737 in a while. Interesting.
0 · Reply
hollypine4comcast
hollypine4comcast Feb. 2 at 8:32 PM
$VTVT We need a strong encouraging news release before we will see any sustained price movement. This management team does not communicate with retail. I will just hold on but I am
0 · Reply
LongBallBarn
LongBallBarn Feb. 2 at 7:43 PM
$VTVT
0 · Reply
dcajic2
dcajic2 Feb. 2 at 7:15 PM
$VTVT Added a few shorts. Figure if it was really going to be bullish volume would be so much higher.
0 · Reply
GDS_investing
GDS_investing Feb. 2 at 6:14 PM
$VTVT very low float need more volume to move on long
0 · Reply
km1663
km1663 Feb. 2 at 5:47 PM
$VTVT Good volume & price action with this Newsoara Bio news. Already passed 65 day average of 15.19k.
0 · Reply
GDS_investing
GDS_investing Feb. 2 at 3:58 PM
$VTVT great NEWS out:"vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737" https://finance.yahoo.com/news/vtv-therapeutics-amends-license-agreement-130000686.html long $VTVT watch $SPY $SOXL
0 · Reply
Bullfinch
Bullfinch Feb. 2 at 1:40 PM
$VTVT https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-amends-license-agreement-newsoara-biopharma-co
0 · Reply
JohnWick0
JohnWick0 Feb. 2 at 1:07 PM
$VTVT vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737 🤔
0 · Reply
Aawilliam2003
Aawilliam2003 Jan. 31 at 5:13 PM
$VTVT these guys have 4 million shares outstanding but another 14 millions warrants. So full diluted market cap is more like 18M X $35 = $630 Million. That is pretty rich given they will likely need to do another phase 3 trial. Wouldn’t touch it here
1 · Reply
dcajic2
dcajic2 Jan. 30 at 6:44 PM
$VTVT Trying again for another short. This company has such a long way to go before any positives.
0 · Reply
dcajic2
dcajic2 Jan. 30 at 3:52 PM
$VTVT There no interest. No chance of making any money anytime soon. Company has a habit of not saying anything. Maybe eventually they have a good day but don’t see it happening anytime soon. Had breakthru therapy for many many years now and hasn’t proven they can even survive in the long run.
0 · Reply
Ctgould
Ctgould Jan. 29 at 1:55 PM
$VTVT Really? You dont understand how analysts make decisions on upgrades/downgrades? You may want to read a book dude. Until then… please dont post.
1 · Reply
dcajic2
dcajic2 Jan. 28 at 2:34 PM
$VTVT don’t understand upgrades. This company tells stock holders pretty much nothing. How can there be upgrades without news
0 · Reply
GDS_investing
GDS_investing Jan. 27 at 3:51 PM
$VTVT and more upgrade news: "BTIG Raises Price Target to $49.00, Maintains Buy Rating | VTVT Stock News" https://www.gurufocus.com/news/8553367/vtvt-btig-raises-price-target-to-4900-maintains-buy-rating-vtvt-stock-news?utm_source=marketwatch&utm_medium=syndication&utm_campaign=headlines&r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news big upside here LONG $VTVT watch $MOVE.X $GITS $SPY
0 · Reply